Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 404

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 404
---
90, which effectively resolved the creditor claim. CoreRX, Inc. On December 11, 2023, NLS received a notice alleging several causes of action, including a failure to remit payment for services rendered by CoreRX. On December 11, 2023, NLS and CoreRX agreed to a structured payment plan in which NLS agreed to pay CoreRX a total amount of $1,007,700.50. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in the amount of $511,835, which effectively resolved the creditor claim. Université de Lausanne On August 27, 2024, the Company received correspondence from Université de Lausanne, initiating the official “audience de conciliation” procedure, overseen by the ordinary civil court in Lausanne. The hearing was scheduled for October 9, 2024, at the Tribunal d’arrondissement de Lausanne. The complaint pertains to an unpaid invoice for research services amounting to $110,179, plus interest at a rate of 5%. At the hearing on October 9, 2024, Université de Lausanne was not open to discussing a potential settlement. The Company asserts that the services provided did not meet the required standard of care and intends to defend its position. On May 9, 2025, the Company filed a statement of defense and asserted a counterclaim in CHF 30,000 plus compensatory interests at a rate of 5% per annum since June 29, 2022. Exchange Controls There are no Swiss governmental laws, decrees or regulations that restrict, in a manner material to NLS, the export or import of capital, including any foreign exchange controls, or that generally affect the remittance of dividends or other payments to non -residentsor non -citizensof Switzerland who hold NLS Common Shares. 202 KADIMASTEM BUSINESS Kadimastem is a clinical -stagepharmaceutical company focused on developing and manufacturing “off -the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of hESCs into functional cells. Kadimastem’s vision is to: •Replace, restore and repair the functionality of diseased and malfunctioning cells in various degenerative diseases by transplantation of healthy and functional cells; and •Commercialize its proprietary cell lines optimized for both